Kevin Lee, Bicycle Therapeutics CEO
September 7, 2022 10:53 AM EDT
R&D

Shoot­ing for a heav­i­ly pre-treat­ed niche can­cer mar­ket, Bi­cy­cle re­veals a 'mixed' da­ta cut

Max Gelman

Senior Editor

Less than two months af­ter ex­pand­ing its im­muno-on­col­o­gy part­ner­ship with Roche’s Genen­tech, Bi­cy­cle Ther­a­peu­tics tout­ed some new in-house da­ta on its lead pro­gram. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times